Analysts Set Labcorp Holdings Inc. (NYSE:LH) Target Price at $308.00

Shares of Labcorp Holdings Inc. (NYSE:LH) have been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $308.00.

LH has been the subject of several research reports. Wall Street Zen lowered shares of Labcorp from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Robert W. Baird set a $334.00 target price on shares of Labcorp in a research report on Friday, May 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Finally, Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th.

Labcorp Trading Up 0.5%

Labcorp stock opened at $266.57 on Tuesday. The stock has a market cap of $21.86 billion, a P/E ratio of 23.61, a PEG ratio of 1.86 and a beta of 0.90. Labcorp has a fifty-two week low of $241.81 and a fifty-two week high of $293.72. The firm’s fifty day moving average price is $260.87 and its 200-day moving average price is $265.44. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73.

Labcorp (NYSE:LH) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter in the prior year, the firm posted $3.84 earnings per share. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Equities research analysts forecast that Labcorp will post 18 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Friday, May 29th were given a $0.72 dividend. The ex-dividend date was Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s payout ratio is 25.51%.

Insider Buying and Selling at Labcorp

In other Labcorp news, EVP Kathryn W. Kyle sold 762 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total transaction of $201,084.18. Following the completion of the sale, the executive vice president directly owned 3,813 shares in the company, valued at $1,006,212.57. This represents a 16.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the sale, the chief executive officer owned 107,234 shares of the company’s stock, valued at approximately $27,291,053. The trade was a 5.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.84% of the stock is currently owned by insiders.

Institutional Trading of Labcorp

Institutional investors have recently added to or reduced their stakes in the business. JPL Wealth Management LLC purchased a new stake in Labcorp during the third quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Labcorp during the fourth quarter valued at about $26,000. Hilton Head Capital Partners LLC purchased a new stake in Labcorp during the fourth quarter valued at about $27,000. Eagle Bay Advisors LLC purchased a new stake in Labcorp during the fourth quarter valued at about $29,000. Finally, DV Equities LLC bought a new position in shares of Labcorp during the fourth quarter valued at about $29,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.